The Conversation (0)
Endologix Announces First US Commercial Implant of AFX®2 Bifurcated Endograft System
Mar. 01, 2016 09:45AM PST
Biotech InvestingEndologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first US commercial implant of the Company’s AFX®2 Bifurcated Endograft System was performed at Maine Medical Center (MMC), in Portland, ME. The procedure was performed by Paul Bloch, M.D., Associate Professor at Tufts University School of Medicine and vascular surgeon at MMC.
Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first US commercial implant of the Company’s AFX®2 Bifurcated Endograft System was performed at Maine Medical Center (MMC), in Portland, ME. The procedure was performed by Paul Bloch, M.D., Associate Professor at Tufts University School of Medicine and vascular surgeon at MMC.
According to the news:
AFX2 reduces procedure steps for the delivery and deployment of the bifurcated endograft. The new device also facilitates percutaneous endovascular aneurysm repair, or PEVAR, by providing the lowest profile contralateral access through a 7F introducer. These improvements bring together Endologix’s ActiveSeal™ technology, DuraPly™ ePTFE graft material and VELA™ Proximal Endograft, into an integrated new EVAR system.
Dr. Sean Lyden, Chairman of Vascular Surgery, Cleveland Clinic and Dr. Dan Clair, Chairman Emeritus, Cleveland Clinic performed their first procedure with AFX2 and commented:
The AFX2 system combines the unique clinical benefits of anatomical fixation with an easier to use, lower-profile delivery system. We are pleased to be amongst the first users of the new AFX2 system, and are excited to offer this next-generation system to our patients.